HDAC4 and breast cancer: These outcomes suggest that dysregulations of HDAC2, HDAC4, and HDAC5 can collaborate with the development of tamoxifen resistance in ER+ breast cancer cells associated with miR-10b and miR-125a-5p deregulation.